Asthika Goonewardene
Stock Analyst at Truist Financial
(2.82)
# 2,667
Out of 4,386 analysts
321
Total ratings
41.5%
Success rate
1.5%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Asthika Goonewardene
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AVBP ArriVent BioPharma | Initiated Coverage: Buy | $43 → $45 | $30.50 | +47.54% | 4 | May 29, 2026 | |
| ACET Adicet Bio | Reiterated: Buy | n/a | $7.22 | - | 14 | Mar 16, 2026 | |
| ALLO Allogene Therapeutics | Maintained: Buy | $10 | $1.85 | +440.54% | 20 | Mar 13, 2026 | |
| BNTX BioNTech SE | Maintained: Buy | $155 | $85.50 | +81.29% | 19 | Mar 13, 2026 | |
| LEGN Legend Biotech | Maintained: Buy | $70 | $31.52 | +122.08% | 10 | Mar 13, 2026 | |
| RVMD Revolution Medicines | Maintained: Buy | n/a | $148.49 | - | 9 | Mar 9, 2026 | |
| CRBU Caribou Biosciences | Reiterated: Buy | $7 | $1.84 | +280.43% | 11 | Mar 9, 2026 | |
| CGEN Compugen | Reiterated: Buy | $4 | $2.04 | +96.08% | 20 | Mar 3, 2026 | |
| ZYME Zymeworks | Reiterated: Buy | $40 | $23.93 | +67.15% | 4 | Mar 3, 2026 | |
| SEPN Septerna | Maintained: Buy | n/a | $30.41 | - | 1 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $30 | $23.32 | +28.64% | 22 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $4.00 | - | 28 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $48 | $24.80 | +93.55% | 40 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $35 | $14.11 | +148.05% | 19 | Feb 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $51 | $51.74 | -1.43% | 30 | Jan 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 → $8 | $1.46 | +447.95% | 25 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $25.41 | - | 17 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $127 → $145 | $128.10 | +13.19% | 12 | Nov 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $197.21 | n/a | 1 | Apr 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $8.08 | n/a | 4 | Mar 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.81195 | n/a | 6 | Jan 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $19 → $15 | $2.79 | n/a | 3 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | kr 265.55 → kr 343.28 | $1,574.00 | n/a | 2 | Jul 14, 2022 |
ArriVent BioPharma
May 29, 2026
Initiated Coverage: Buy
Price Target: $43 → $45
Current: $30.50
Upside: +47.54%
Adicet Bio
Mar 16, 2026
Reiterated: Buy
Price Target: n/a
Current: $7.22
Upside: -
Allogene Therapeutics
Mar 13, 2026
Maintained: Buy
Price Target: $10
Current: $1.85
Upside: +440.54%
BioNTech SE
Mar 13, 2026
Maintained: Buy
Price Target: $155
Current: $85.50
Upside: +81.29%
Legend Biotech
Mar 13, 2026
Maintained: Buy
Price Target: $70
Current: $31.52
Upside: +122.08%
Revolution Medicines
Mar 9, 2026
Maintained: Buy
Price Target: n/a
Current: $148.49
Upside: -
Caribou Biosciences
Mar 9, 2026
Reiterated: Buy
Price Target: $7
Current: $1.84
Upside: +280.43%
Compugen
Mar 3, 2026
Reiterated: Buy
Price Target: $4
Current: $2.04
Upside: +96.08%
Zymeworks
Mar 3, 2026
Reiterated: Buy
Price Target: $40
Current: $23.93
Upside: +67.15%
Septerna
Mar 2, 2026
Maintained: Buy
Price Target: n/a
Current: $30.41
Upside: -
Feb 27, 2026
Reiterated: Buy
Price Target: $30
Current: $23.32
Upside: +28.64%
Feb 25, 2026
Maintained: Hold
Price Target: n/a
Current: $4.00
Upside: -
Feb 25, 2026
Reiterated: Buy
Price Target: $48
Current: $24.80
Upside: +93.55%
Feb 24, 2026
Reiterated: Buy
Price Target: $35
Current: $14.11
Upside: +148.05%
Jan 14, 2026
Reiterated: Buy
Price Target: $51
Current: $51.74
Upside: -1.43%
Jan 13, 2026
Reiterated: Buy
Price Target: $10 → $8
Current: $1.46
Upside: +447.95%
Nov 11, 2025
Maintained: Buy
Price Target: n/a
Current: $25.41
Upside: -
Nov 3, 2025
Reiterated: Buy
Price Target: $127 → $145
Current: $128.10
Upside: +13.19%
Apr 24, 2024
Maintained: Hold
Price Target: n/a
Current: $197.21
Upside: n/a
Mar 21, 2024
Rated: Hold
Price Target: n/a
Current: $8.08
Upside: n/a
Jan 16, 2024
Rated: Hold
Price Target: n/a
Current: $0.81195
Upside: n/a
Aug 23, 2022
Maintained: Buy
Price Target: $19 → $15
Current: $2.79
Upside: n/a
Jul 14, 2022
Maintained: Buy
Price Target: kr 265.55 → kr 343.28
Current: $1,574.00
Upside: n/a